Customise Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.

Team

Shomit Sengupta headshot
SHOMIT SENGUPTA, PhD
Vice President, Head of Biology

Shomit Sengupta brings over 10 years of drug discovery experience focused on metabolism and related signaling pathways to Atavistik Bio. He is an accomplished scientist and manager with a strong publication record and experience in both early and late-stage drug development. Most recently, Shomit was an Associate Director at Agios Pharmaceuticals, where he managed teams of scientists responsible for validating new therapeutic targets and evaluating new indications for existing assets for the rare genetic disease portfolio. He joined Agios from Navitor Pharmaceuticals where he was the lead biologist from discovery to IND for a first-in-class modulator of leucine sensing for treatment-resistant depression. Prior to Navitor, Shomit worked on cell pharmacology screening efforts at the Center for the Development of Therapeutics at the Broad Institute, and the development and execution of clinical biomarker assays at Catabasis Pharmaceuticals.

Shomit received his PhD in Biology from the Whitehead Institute at MIT and did his postdoctoral training in the lab of Joan Brugge at Harvard Medical School.